Notice for Dexrazoxane (Reach Pharmaceuticals Pty Ltd)
Active ingredients
Dexrazoxane
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
powder for injection
Indication
For use in the prevention of cardiotoxicity caused by anthracycline use
Therapeutic area
Cardiovascular